mex-3 RNA binding family member BGenealiases: MEX-3B · RKHD3 · RNF195
Q-omics provides the consensus-scored MEX3B profile across patient tissues and cancer cell-line models. MEX3B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MEX3B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MEX3B RNA expression shows 20,053 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where MEX3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEX3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEX3B survival associations across molecular data types. MEX3B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEX3B RNA expression–survival associations across cancer types. High MEX3B expression shows unfavorable associations in MESO, ACC, UVM and THCA, but favorable associations in UCS and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MEX3B RNA expression.
This table summarizes MEX3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MEX3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEX3B shows higher tumor expression in KIRC, HNSC, KIRP, COAD, LUAD and LIHC. The KIRC box plot shows higher MEX3B RNA expression in tumor versus normal tissue (log2 FC = +0.685, t-test p < 0.001).
This table shows molecular features associated with MEX3B in patient tissues and cancer cell lines. In patient samples, MEX3B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEX3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
